383 related articles for article (PubMed ID: 22003072)
1. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
[TBL] [Abstract][Full Text] [Related]
2. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
[TBL] [Abstract][Full Text] [Related]
3. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
4. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.
Hicks SW; Tarantelli C; Wilhem A; Gaudio E; Li M; Arribas AJ; Spriano F; Bordone R; Cascione L; Lai KC; Qiu Q; Taborelli M; Rossi D; Stussi G; Zucca E; Stathis A; Sloss CM; Bertoni F
Haematologica; 2019 Aug; 104(8):1633-1639. PubMed ID: 30733273
[TBL] [Abstract][Full Text] [Related]
5. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Ribrag V; Dupuis J; Tilly H; Morschhauser F; Laine F; Houot R; Haioun C; Copie C; Varga A; Lambert J; Hatteville L; Ziti-Ljajic S; Caron A; Payrard S; Coiffier B
Clin Cancer Res; 2014 Jan; 20(1):213-20. PubMed ID: 24132920
[TBL] [Abstract][Full Text] [Related]
6. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2013 Apr; 19(7):1795-805. PubMed ID: 23426279
[TBL] [Abstract][Full Text] [Related]
7. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
8. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Robak T
Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
[TBL] [Abstract][Full Text] [Related]
9. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.
Trnĕný M; Verhoef G; Dyer MJ; Ben Yehuda D; Patti C; Canales M; Lopez A; Awan FT; Montgomery PG; Janikova A; Barbui AM; Sulek K; Terol MJ; Radford J; Guidetti A; Di Nicola M; Siraudin L; Hatteville L; Schwab S; Oprea C; Gianni AM
Haematologica; 2018 Aug; 103(8):1351-1358. PubMed ID: 29748443
[TBL] [Abstract][Full Text] [Related]
10. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
11. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Younes A; Kim S; Romaguera J; Copeland A; Farial Sde C; Kwak LW; Fayad L; Hagemeister F; Fanale M; Neelapu S; Lambert JM; Morariu-Zamfir R; Payrard S; Gordon LI
J Clin Oncol; 2012 Aug; 30(22):2776-82. PubMed ID: 22753910
[TBL] [Abstract][Full Text] [Related]
12. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Ward E; Mittereder N; Kuta E; Sims GP; Bowen MA; Dall'Acqua W; Tedder T; Kiener P; Coyle AJ; Wu H; Jallal B; Herbst R
Br J Haematol; 2011 Nov; 155(4):426-37. PubMed ID: 21902688
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
Multani PS; O'Day S; Nadler LM; Grossbard ML
Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
[TBL] [Abstract][Full Text] [Related]
14. Eradication of CD19+ leukemia by targeted calicheamicin θ.
Bernt KM; Prokop A; Huebener N; Gaedicke G; Wrasidlo W; Lode HN
Bioconjug Chem; 2009 Aug; 20(8):1587-94. PubMed ID: 19572629
[TBL] [Abstract][Full Text] [Related]
15. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
[TBL] [Abstract][Full Text] [Related]
16. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
17. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
18. Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment.
Li Z; Wang M; Yao X; Li H; Li S; Liu L; Yu D; Li X; Fang J; Huang C
Int Immunopharmacol; 2018 Sep; 62():299-308. PubMed ID: 30048860
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
Leonard JP; Goldenberg DM
Oncogene; 2007 May; 26(25):3704-13. PubMed ID: 17530024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]